BCAB
BioAtla Inc

1,313
Loading...
Loading...
News
all
press releases
Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism
Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.
Stocktwits·10mo ago
News Placeholder
More News
News Placeholder
Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook
Justin Zelin, an analyst from BTIG, reiterated the Buy rating on BioAtla (BCAB Research Report). The associated price target was raised to $13.00...
TipRanks Financial Blog·1y ago
News Placeholder
Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential
BioAtla (BCAB Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Secur...
TipRanks Financial Blog·1y ago
News Placeholder
Analysts Set Expectations for BioAtla, Inc.'s FY2028 Earnings (NASDAQ:BCAB)
BioAtla, Inc. (NASDAQ:BCAB - Free Report) - Investment analysts at HC Wainwright issued their FY2028 earnings estimates for BioAtla in a research report issued to clients and investors on...
Zolmax·1y ago
News Placeholder
BioAtla (NASDAQ:BCAB) PT Lowered to $7.00
BioAtla (NASDAQ:BCAB - Free Report) had its price objective lowered by HC Wainwright from $10.00 to $7.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a buy rating...
Ticker Report·1y ago
News Placeholder
BioAtla (NASDAQ:BCAB) Stock Rating Reaffirmed by JMP Securities
BioAtla (NASDAQ:BCAB - Get Free Report)s stock had its "market outperform" rating restated by analysts at JMP Securities in a report issued on Thursday, Benzinga reports. They presently have a...
Zolmax·1y ago
News Placeholder
BioAtla (NASDAQ:BCAB) PT Lowered to $7.00
BioAtla (NASDAQ:BCAB Get Free Report) had its target price reduced by equities researchers at HC Wainwright from $10.00 to $7.00 in a research report issued on Wednesday, Benzinga reports...
Zolmax·1y ago
News Placeholder
BioAtla (BCAB, $3.46) RSI Indicator left the overbought zone on March 27, 2024
This is a signal that BCAB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Wall Street Analysts Are Bullish on Top Healthcare Picks
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioAtla (BCAB Research Report) and Crinetics Pharmaceuticals...
TipRanks Financial Blog·1y ago
News Placeholder
Q4 2023 Bioatla Inc Earnings Call Transcript
Related Stocks: NAS:BCAB...
GuruFocus·1y ago

Latest BCAB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.